EUCTR2009-009919-21-IT进行中（未招募）不适用
Antiangiogenic activity of metronomic therapy with capecitabine in metastatic solid tumors of gastrointestinal tract: a phase II study - Metronomic capecitabine
ISTITUTO DERMOPATICO IMMACOLATA0 个研究点开始时间: 2009年11月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically or cytologically confirmed colorectal or gastric or colangio- or pancreatic carcinoma metastastic or locally advanced disease, not amenable to surgery. At least 1 prior chemotherapy regimen for metastatic disease for patients with ECOG PS 0-1 No prior chemotherapy regimen is scheduled for patients with an ECOG performance status of 2 At least one measurable tumor lesion according to the Response Evaluation Criteria in Solid Tumors RECIST criteria Patients over 18 ECOG Performance Status < 2 Signed informed consent.Consenso informato scritto
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Life expectancy < 3 months serious and uncontrolled systemic co-morbidities second malignancy (except adequately treated in situ carcinoma of the cervix or non melanomic skin cancer) Patients who are pregnant or breast-feeding.
研究者
相似试验
进行中（未招募）
不适用
Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding studyadvanced and/or metastatic pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticEUCTR2006-003403-39-DEovartis Pharma GmbH
进行中（未招募）
不适用
Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within theSwedish Association of Breast Oncologists SABO-2010-01Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC) can also be included. Patients with TNBC will not receive endocrine therapy.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022065-10-SESahlgrenska University Hospital
招募中
不适用
A new treatment for skin ulcers associated with systemic sclerosis using the ability of own bone marrow cells to regenerate blood vesselsSystemic sclerosis, Vasculopathy, Skin ulcer, Raynaud's phenomenonSystemic sclerosisJPRN-jRCTb032210204Yoshimi Ryusuke12
招募中
Unknown
Multi-parametric profiling of cancer patient samples and metronomic chemotherapy for forensic and treatment outcomes.CTRI/2024/07/070026A
终止
2 期
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast CancerChemotherapyBreast Cancer, MetastaticNCT01067989HaEmek Medical Center, Israel22